Skip to content

Economic Evaluation of Treatment Modalities for Position Dependent Obstructive Sleep Apnea

Economic Evaluation of Treatment Modalities for Position Dependent Obstructive Sleep Apnea Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02553902
Enrollment
200
Registered
2015-09-18
Start date
2015-09-30
Completion date
2019-12-31
Last updated
2018-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Positional Obstructive Sleep Apnea

Keywords

Positional therapy, MAD, Oral appliance, Sleep position trainer, POSA

Brief summary

OBJECTIVES: To evaluate the effect and cost-utility of a combination therapy of SPT+MAD compared with continuous positive airway pressure (CPAP) in patients with moderate positional obstructive sleep apnea (POSA). HYPOTHESIS: The SPT+MAD combination is more cost-effective and effective, in means of reduction of the apnea-hypopnea index (AHI), quality of life and compliance, compared with CPAP. STUDY DESIGN: A multicenter randomized clinical trial (RCT) will be performed with a follow-up of 12 months per patient. Patients will be randomized for CPAP or the combination SPT and MRA. All outcomes will be measured at baseline, month 3, 6 and 12. STUDY POPULATION: Patients diagnosed with moderate POSA according to polysomnography (PSG) results. INTERVENTION / STANDARD INTERVENTION TO BE COMPARED TO: The SPT trains POSA patients to sleep in non-supine positions, CPAP uses positive airway pressure to open the airway; MRA is an intra-oral prosthesis, which holds the mandible in a protrusive position, all to prevent effectively apneic events. OUTCOME MEASURES: AHI, compliance, quality-adjusted life year (QALY), direct and indirect costs, cardiovascular parameters, incremental cost-effectiveness ratio (ICER) SAMPLE SIZE / DATA ANALYSIS: 100 subjects in each treatment group, total of 200 patients. COST-EFFECTIVENESS ANALYSIS / BUDGET IMPACT ANALYSIS: The SPT is expected to improve the cost-effectiveness of overall treatment of POSA patients, and will save annually approximately 35-150 million euros.

Interventions

DEVICEContinuous positive airway pressure
DEVICEMandibular advancement device

Sponsors

University Hospital, Antwerp
CollaboratorOTHER
Onze Lieve Vrouwe Gasthuis
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years and older * Ability to speak, read and write Dutch * Ability to follow up * Diagnosis with symptomatic moderate OSA (15 \< AHI \< 30) * Diagnosis of 10 to 90% supine position during the night * AHI supine is 2 \> as high as AHI non-supine * Own a Windows PC and ability to install SPT connection software and upload research data * Expected to maintain current lifestyle (sports, medicine, diet etc.)

Exclusion criteria

* Many dental problems; insufficient teeth for wearing MRA * Medication used/ related to sleeping disorders * Central Sleep Apnea Syndrome * Night or shifting work * Severe chronic heart failure * Medical history of known causes of tiredness by day or severe sleep disruption (insomnia, PLMS, Narcolepsy) * Seizure disorder * Known medical history of mental retardation, memory disorders or psychiatric disorders * Shoulder, neck and back complaints * Reversible morphological upper airway abnormalities (e.g. enlarged tonsils) * Inability to provide informed consent * Simultaneous use of other treatment modalities to treat OSA * Previous treatment for OSA with MRA, CPAP or SPT * Pregnancy

Design outcomes

Primary

MeasureTime frame
Apnea-hypopnea index (AHI)change from baseline, after 3, 6 and 12 months

Secondary

MeasureTime frameDescription
Outcome of Quality of Life questionnaireschange from baseline, after 3, 6 and 12 monthsEQ-5D
(Societal) costs of treatmentchange from baseline, after 3, 6 and 12 monthsiMTA Productivity Cost Questionnaire (iPCQ)
Therapy compliancechange from baseline, after 3, 6 and 12 monthsMeasurement of actual wearing time (in hours) per night
Cardiovascular parameterschange from baseline, after 3, 6 and 12 monthsSystolic and diastolic blood pressure

Countries

Belgium, Netherlands

Contacts

Primary ContactPatty Vonk, MD
researchkno@olvg.nl
Backup ContactN de Vries, Professor
n.vries@slaz.nl

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026